$1.28
3.23% yesterday
Nasdaq, Oct 15, 10:02 pm CET
ISIN
US3741631036
Symbol
GERN

Geron Corporation Stock price

$1.28
+0.01 0.79% 1M
+0.03 2.40% 6M
-2.26 63.84% YTD
-2.91 69.45% 1Y
-1.01 44.10% 3Y
-0.72 36.00% 5Y
-1.99 60.86% 10Y
-7.60 85.58% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+0.04 3.23%
ISIN
US3741631036
Symbol
GERN
Industry

Key metrics

Basic
Market capitalization
$816.7m
Enterprise Value
$547.7m
Net debt
positive
Cash
$388.0m
Shares outstanding
637.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.0 | 3.9
EV/Sales
3.3 | 2.6
EV/FCF
negative
P/B
3.2
Financial Health
Equity Ratio
47.2%
Return on Equity
-62.3%
ROCE
-16.1%
ROIC
-
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$164.5m | $211.9m
EBITDA
$-78.0m | $-81.0m
EBIT
$-79.1m | $-65.7m
Net Income
$-88.0m | $-72.5m
Free Cash Flow
$-178.3m
Growth (TTM | estimate)
Revenue
11,903.7% | 175.2%
EBITDA
65.6% | 53.0%
EBIT
65.2% | 62.2%
Net Income
59.9% | 58.5%
Free Cash Flow
14.5%
Margin (TTM | estimate)
Gross
97.8%
EBITDA
-47.4% | -38.3%
EBIT
-48.1%
Net
-53.5% | -34.2%
Free Cash Flow
-108.4%
More
EPS
$-0.1
FCF per Share
$-0.3
Short interest
14.7%
Employees
229
Rev per Employee
$340.0k
Show more

Is Geron Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Geron Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Geron Corporation forecast:

11x Buy
73%
3x Hold
20%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Geron Corporation forecast:

Buy
73%
Hold
20%
Sell
7%

Financial data from Geron Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
164 164
11,904% 11,904%
100%
- Direct Costs 3.64 3.64
18,100% 18,100%
2%
161 161
18,384% 18,384%
98%
- Selling and Administrative Expenses 158 158
49% 49%
96%
- Research and Development Expense 80 80
34% 34%
49%
-78 -78
66% 66%
-47%
- Depreciation and Amortization 1.13 1.13
22% 22%
1%
EBIT (Operating Income) EBIT -79 -79
65% 65%
-48%
Net Profit -88 -88
60% 60%
-54%

In millions USD.

Don't miss a Thing! We will send you all news about Geron Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Geron Corporation Stock News

Neutral
GlobeNewsWire
2 days ago
Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations
Positive
Seeking Alpha
6 days ago
How to trade and invest in the biotech space, according to ROTY Biotech Community's Jonathan Faison. Favoring late-stage, commercial-stage companies with clear paths to profitability and strong sales ramp potential.
Neutral
GlobeNewsWire
28 days ago
FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 966,000 shares of its common stock, consisting of stock options to purchase an aggregate of 644,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate o...
More Geron Corporation News

Company Profile

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Head office United States
CEO Dawn Bir
Employees 229
Founded 1990
Website www.geron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today